Test Price
1,600 AED✅ Home Collection Available
PDGFR Mutation Screening (Exons 12, 14, 18) in UAE | 1600 AED
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139). Target-specific Sanger Sequencing with bidirectional coverage of PDGFRA exons 12, 14, and 18 ensures definitive mutation detection for GIST and related oncologic conditions.
Secure Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval from your treating hospital or histopathology archive. Temperature-controlled chain-of-custody transport of FFPE blocks or fresh frozen tissue directly to our ISO-certified laboratory, available daily from 8 AM to 11 PM, fully compliant with UAE PDPL data privacy standards.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by DHA-licensed genetics and oncology specialists. Results delivered in 7–8 working days with actionable clinical correlation.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. We coordinate with major UAE insurers for seamless pre-authorization.
Test Overview & Methodology
PDGFR Mutation Screening (Exons 12, 14, 18) is a precision oncology genetic test that detects activating mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene using gold-standard Sanger Sequencing. This test is essential for identifying actionable driver mutations in gastrointestinal stromal tumors (GIST) — particularly in KIT-wildtype cases — and guides targeted therapy decisions with tyrosine kinase inhibitors such as imatinib. A valid doctor's prescription is required for testing. The specimen must be accompanied by the original histopathology report confirming tumor diagnosis. Minimum tissue requirement: one FFPE block or 10 unstained slides (5-micron thickness).
| Parameter | Our Test — Sanger Sequencing | Closest Alternative — NGS Panel |
|---|---|---|
| Analytical Precision | >99.9% per-base accuracy; bidirectional exon coverage | ~99.5% per-base; depth-dependent sensitivity |
| Methodology | Sanger Sequencing — Gold Standard for targeted exon analysis | Next-Generation Sequencing (NGS) — multi-gene panel |
| Turnaround Time | 7–8 Working Days | 10–21 Working Days (batch-dependent) |
| Cost Efficiency | 1600 AED — focused, cost-effective for PDGFRA-specific queries | 2500–4500 AED — broader but higher cost for targeted question |
| Clinical Applicability | Optimal for KIT-wildtype GIST; imatinib sensitivity confirmation | Broader profiling; may include genes irrelevant to current query |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (DHA: 9294403) — "A positive PDGFRA mutation in exons 12, 14, or 18 provides critical molecular stratification for GIST management, distinguishing imatinib-sensitive genotypes from primary resistant variants such as D842V. This genetic finding must be interpreted alongside histopathological parameters including tumor size, mitotic index, and surgical margins. Patients should understand that molecular results alone do not dictate therapy — multidisciplinary tumor board review remains essential for personalized treatment planning."
Medication Advisory — Do Not Self-Adjust Therapy
If you are currently receiving tyrosine kinase inhibitor therapy (e.g., imatinib, sunitinib, regorafenib, avapritinib), do not interrupt or adjust your dosage based on genetic test results alone. All therapeutic modifications must be supervised by your treating oncologist. Genetic findings complement but do not replace clinical judgment.
Exclusion Criteria & Emergency Red Flags
- Inadequate Tumor Tissue: Specimens with less than 20% tumor cellularity may yield inconclusive results. Histopathological review is required prior to DNA extraction.
- Decalcified or Poorly Preserved Samples: Bone tumor specimens subjected to strong acid decalcification or tissues fixed in non-buffered formalin are unsuitable for Sanger Sequencing due to DNA degradation.
- Minors: Genetic testing in patients under 18 years requires explicit parental or legal guardian consent as mandated by Federal Decree-Law No. 4 of 2016 on Medical Liability. Guardian must be present during sample collection.
- ER Red Flags — Seek Immediate Medical Attention: If you experience sudden severe abdominal pain, gastrointestinal bleeding (hematemesis or melena), acute weight loss exceeding 5 kg in one month, or tumor-related fever unresponsive to antipyretics, proceed to the nearest emergency department. These symptoms may indicate tumor rupture or rapid progression requiring urgent intervention — do not wait for genetic test results.
- Pregnancy: This test is not applicable as a standalone diagnostic during pregnancy. Clinical correlation with maternal-fetal medicine specialists is mandatory if oncologic evaluation is required during gestation.
Patient FAQ & Clinical Guidance
1. What does a positive PDGFRA mutation result mean for my GIST treatment?
A positive PDGFRA mutation in exons 12, 14, or 18 confirms your gastrointestinal stromal tumor has an identifiable driver mutation that is generally sensitive to targeted therapy with imatinib, excepting the D842V exon 18 variant which is primarily resistant and may require alternative agents such as avapritinib. Your oncologist will integrate this molecular finding with tumor size, location, mitotic index, and rupture risk to formulate a personalized treatment plan. The presence of a PDGFRA mutation — particularly in KIT-wildtype GIST — is a favorable prognostic indicator when paired with appropriate tyrosine kinase inhibitor selection. Post-test telephonic guidance with our DHA-licensed specialists will walk you through every clinically actionable detail of your report.
2. Why choose Sanger Sequencing over Next-Generation Sequencing for PDGFRA testing?
Sanger Sequencing delivers superior per-base analytical accuracy exceeding 99.9% for targeted exon analysis, making it the definitive reference-standard method for PDGFRA exon 12, 14, and 18 mutation screening when the clinical question is focused rather than exploratory. Unlike broad NGS panels that may introduce depth-dependent false negatives, bidirectional Sanger sequencing provides unambiguous nucleotide-level resolution across every codon of the three clinically actionable exons. For UAE patients requiring rapid, cost-effective, and clinically decisive results — particularly in the neo-adjuvant or pre-imatinib setting — this focused approach reduces both turnaround time (7–8 days vs. 10–21 days) and cost (1600 AED vs. 2500–4500 AED) without compromising diagnostic yield.
3. How is the solid tissue specimen retrieval conducted for archival samples in the UAE?
Our Secure Medical Courier Solid Tissue Specimen Retrieval service dispatches a trained medical courier to your treating hospital or histopathology archive anywhere in the UAE between 8 AM and 11 PM, equipped with temperature-controlled transport containers validated for FFPE block and fresh frozen tissue integrity throughout transit. The specimen — either an existing FFPE block retrieved from your histopathology archive or freshly collected tissue — is logged with chain-of-custody documentation, immediately stabilized at 2–8°C, and transported to our ISO 9001:2015 accredited laboratory (DHA Facility License: 1143) within four hours. All patient data is encrypted and processed in full compliance with UAE PDPL regulations. Booking is confirmed via WhatsApp at +971 54 548 8731, and you receive real-time status updates until the sample reaches our molecular diagnostics unit.
UAE Regulatory & Data Privacy Adherence
All genetic testing data is classified as sensitive personal data under the UAE Personal Data Protection Law. Processing, storage, and transmission comply with the PDPL framework for genomic and health data confidentiality.
All electronic health data transmissions, including genomic sequence files and molecular reports, comply with the UAE law on the use of information and communication technology in health fields, ensuring secure digital exchange.
Patient consent protocols, minor guardian authorization, and clinical safety procedures follow the UAE Medical Liability Law, which governs all diagnostic and therapeutic medical practices.
Contact: WhatsApp +971 54 548 8731 | Secure Courier Retrieval: 8 AM – 11 PM Daily | Results: 7–8 Working Days | Price: 1600 AED
Clinical & Logistical Metadata
| Test Name | PDGFR Mutation Screening (Exons 12, 14, 18) |
| Price (AED) | 1600 AED |
| Turnaround Time | 7–8 Working Days |
| Sample Type / Matrix | Archival Tissue Specimen — Formalin-Fixed Paraffin-Embedded (FFPE) Block or Fresh Frozen Tumor Tissue. Minimum 10 unstained slides (5-micron) or one FFPE block. Secure Medical Courier Solid Tissue Specimen Retrieval only; home phlebotomy is disabled for safety. |
| Methodology Used | Bidirectional Sanger Sequencing — Gold standard for targeted exon analysis with >99.9% per-base accuracy |
| ICD-10-CM Code | Z13.89 |
| LOINC Code | 92105-9 |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians